Affiliation:
1. Infectious Diseases Unit, Hospital Doce de Octubre, Madrid, Spain.
Abstract
The efficacy of ganciclovir, given prophylactically, to prevent cytomegalovirus-related disease was evaluated in liver transplant recipients, mostly seropositive, under treatment with OKT3 monoclonal antibodies. The incidence of cytomegalovirus disease and visceral involvement was reduced, respectively, from 52 and 36% in the control group to 12 and 8% in the ganciclovir-treated patients. Leukopenia was a frequent (32%) side effect of ganciclovir administration.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference21 articles.
1. A randomized, placebo controlled trial of oral acyclovir for the prevention of CMV disease after kidney transplantation;Balfour H. H.;N. Engl. J. Med.,1989
2. The role of CMV immunoprophylaxis in patients at risk of primary CMV infection following orthotopic liver transplantation;Bell R.;Transplant. Proc.,1989
3. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection;Drew W. L.;J. Infect. Dis.,1991
4. Cytomegalovirus infection in pediatric liver recipients: a virologic screening and prophylaxis with CMV immunoglobulin and early DHPG treatment;Dussaix E.;Transplantation,1989
5. Comparison of three regimens for cytomegalovirus prophylaxis in 147 liver transplant recipients;Freise C. E.;Transplant. Proc.,1991
Cited by
32 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献